Human serum albumin

被引:0
|
作者
Rie, MA [1 ]
Fahy, BG
Kofke, WA
机构
[1] Univ Kentucky, Med Ctr, Lexington, KY USA
[2] Hosp Univ Penn, Philadelphia, PA 19104 USA
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Object. Human albumin is used to induce hypervolemia (central venous pressure [CVP] > 8 mm Hg) after subarachnoid hemorrhage (SAH). Unfortunately, human albumin may increase the mortality rate in critically ill patients; because of this, its use became restricted in the authors' hospital in May 1999. The goal of this study was to determine the effect of human albumin on outcome and cost in patients with SAH before and after this restriction was put into place. Methods. All patients with aneurysmal SAH who were admitted to the authors' institution between May 1998 and May 2000 were studied. Basic demographic information, dosage of human albumin given, length of stay, and the incidence of in-hospital deaths and complications were collected. The authors obtained Glasgow Outcome Scale (GOS) scores at 3 months after SAH (good outcome, GOS greater than or equal to 4). Data were analyzed using t-test and chi-square analysis. Logistic regression was used to identify independent associations between use of human albumin and outcome. The authors studied 140 patients: 63 who were admitted between May 1998 and May 1999 (Group 1) and 77 treated between June 1999 and May 2000 (Group 2). Two subgroups of patients were further analyzed. Group 1 patients who received human albumin (albumin subgroup, 37 patients) and Group 2 patients who would have received albumin under the old protocol (that is, those who failed to achieve CVP > 8 mm Hg after normal saline administration; nonalbumin subgroup, 47 patients). Patients in the nonalbumin subgroup were more likely to be male (38% compared with 16%), to experience hypertension (55% compared with 30%), to suffer from hypomagnesemia (49% compared with 5.4%), and to have hydrocephalus (47% compared with 27%). There was a trend for these patients to have more vasospasm (28% compared with 19%, p = 0.2). Patients in the albumin subgroup were more likely to have a good outcome at 3 months. Conclusions. Administration of human albumin after SAH may improve clinical outcome and reduce hospital cost.
引用
收藏
页码:564 / 566
页数:3
相关论文
共 50 条
  • [1] Rat serum albumin is not equal to human serum albumin
    Zheng, Na
    Zhu, Shaohua
    Liu, Liang
    Yu, Xiaojun
    FERTILITY AND STERILITY, 2011, 95 (08) : E81 - E81
  • [2] Rat serum albumin is not equal to human serum albumin Reply
    Mentese, Ahmet
    Turedi, Suleyman
    Turkmen, Suha
    Gunduz, Abdulkadir
    Uzun, Aysegul
    Kutlu, Omer
    FERTILITY AND STERILITY, 2011, 95 (08) : E82 - E83
  • [3] Mathematical modeling of interactions of cabergoline with human serum albumin for biosensing of human serum albumin
    Jalalvand, Ali R.
    Ghobadi, Sirous
    Akbari, Vali
    Goicoechea, Hector C.
    Faramarzi, Elahe
    Mahmoudi, Majid
    SENSING AND BIO-SENSING RESEARCH, 2019, 25
  • [4] Human serum albumin - Response
    Heros, RC
    JOURNAL OF NEUROSURGERY, 2004, 101 (03) : 566 - 566
  • [5] Human serum albumin in neurodegeneration
    Shojai, Sajjad
    Rohani, Seyed-Ali Haeri
    Moosavi-Movahedi, Ali Akbar
    Habibi-Rezaei, Mehran
    REVIEWS IN THE NEUROSCIENCES, 2022, 33 (07) : 803 - 817
  • [6] Crystallisation of human serum albumin
    Adair, ME
    Taylor, GL
    NATURE, 1935, 135 : 307 - 307
  • [7] HUMAN SERUM ALBUMIN IN NEPHROSIS
    不详
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1948, 136 (04): : 251 - 251
  • [8] Imaging Human Serum Albumin
    Chicea, Dan
    Chicea, Liana Maria
    Chicea, Radu
    PHYSICS CONFERENCE (TIM-10), 2011, 1387
  • [9] ON HETEROGENEITY OF HUMAN SERUM ALBUMIN
    SPONAR, J
    FRIC, I
    KOVARIKOVA, J
    STOKROVA, S
    COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, 1963, 28 (07) : 1831 - &
  • [10] Recombinant human serum albumin
    Chuang, Victor T. G.
    Otagiri, Masaki
    DRUGS OF TODAY, 2007, 43 (08) : 547 - 561